|
|
|
| Mutations in HBV reverse transcriptase region in patients with chronic hepatitis B after nucleot(s)ide analogues withdrawal |
| LI Quanshuang1,2 DENG Yanchao1,2▲ CHENG Xing2 PEI Yunfeng2 ZHOU Jing2 SHEN Hongyan1,2 XU Zhan1,2 |
1.Xuzhou Institute of Medical Sciences, Jiangsu Province, Xuzhou 221006, China;
2.The Affiliated Xuzhou Central Hospital of Nanjing University of Chinese Medicine, Jiangsu Province, Xuzhou 221006, China |
|
|
|
Abstract Objective To investigate the mutation of hepatitis B viurs DNA reverse transcriptase in chronic hepatitis B patients with relapse after nucleot(s)ide analogues withdrawal. Methods From January 2014 to January 2016, in Xuzhou Central Hospital, 110 serum samples of patients with chronic hepatitis B were collected. Patients took nucleoside (acid) drugs for more than 6 months; due to various reasons, patients after withdrawal of the disease recurrence. HBV resistance mutation sites and genotypes were detected by PCR- reverse dot blot hybridization. Results There were 62 drug resistant mutations, the detection rate was 56.36%; including 36 cases of rtL180M (32.73%), 24 cases of rtM204I (21.82%), 24 cases of rtM204V (21.82%), 14 cases of rtA181V (12.73%); the number of patients with drug resistance was 58 cases (52.73%), and the main patterns of mutation were L180M+M204I/V, M204I, A181V. Drug resistance rates of Lamivudine (LMV), telbivudine (LDT), adefovir dipivoxil (ADV) was 52.73%, 22.73%, 14.55% respectively; there were 43 patients with entecavir resistance risk (39.09%) among them. 24 patients were resistant to LMV and LDT, the ratio was 21.82%; 14 patients were resistant to LMV and ADV, the ratio was 12.73%; 2 patients were resistant to LMV, LDT, ADV, the ratio was 1.82%. Mutations in the HBV RT region were independent of age, sex, genotype (P > 0.05). Conclusion The incidence of drug resistance mutation in chronic hepatitis B patients with relapse after withdrawal was higher; it is necessary to detect the mutations in chronic hepatitis B patients with relapse after withdrawal, so as to provide basis for clinical treatment.
|
|
|
|
|
|
[1] 陈立，李孝楼，甘巧蓉，等.核苷（酸）类似物治疗慢性乙型肝炎停药复发患者的临床特点及其影响因素[J].中华肝脏病杂志，2013，21（11）：825-828.
[2] 张达衡，陈红玲，谭满胜，等.PCR-反向点杂交法检测HBV耐药变异与基因型的探讨[J].国际检验医学杂志，2014，35（13）：1716-1717.
[3] 蒋贝，戴晨阳，李秀梅，等.基于PCR测序技术的HBV感染者耐药突变临床分析[J].中华肝脏病杂志，2016，24（1）：36-39.
[4] 中华医学会肝病学分会.中华医学会感染病学分会.慢性乙型肝炎防治指南（2015年版）[J].中华临床感染病杂志，2015，8（6）：481-503.
[5] 谢巧灵，丛庆伟，吴凌虹，等.耐核苷（酸）类药物慢性乙型肝炎和肝硬化患者血清HBV基因型和P区耐药突变位点分析[J].实用肝脏病杂志，2016，19（1）：60-63.
[6] Ha M，Zhang G，Diao S，et al. A prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients with stringent cessation criteria for adefovir [J]. Arch Virol，2012，157（2）：285-290.
[7] Liang Y，Jiang J，Su M，et al. Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy [J]. Aliment Pharmacol Ther，2011，34（3）：344-352.
[8] 邱源旺，黄利华，甘建和.慢性乙型肝炎核苷（酸）类药物治疗停药后复发的相关影响因素[J].中华临床感染病杂志，2015，8（6）：567-570.
[9] 戚应杰，岳莉，朱义媛，等.乙型肝炎病毒耐药基因变异位点与基因型及病毒载量的关系[J].国际检验医学杂志，2015，36（3）：392-394.
[10] 戴明佳，方圆，汪莉萍，等.740例HBV感染者血清HBV逆转录酶区耐药位点分析[J].实用肝脏病杂志，2014， 17（3）：255-258.
[11] 汪莉萍，韩方正，李春杨，等.慢性乙型肝炎患者抗病毒治疗前HBV P区基因序列测定的意义[J].中华临床感染病杂志，2011，4（5）：303-305.
[12] 钱福初，秦基取，李栋立，等.拉米夫定治疗后慢性乙肝患者 HBV 基因组 RT 区和S 区变异分析[J].病毒学报，2015，34（4）：433-437.
[13] 汪莉萍，李春杨，韩方正，等.病毒学反弹的慢性乙型肝炎患者病毒多聚酶区耐药突变分析[J].中华传染病杂志，2016，34（10）：593-596.
[14] 郭姝君，李娟，曲沛，等.中国北方地区 HBV 主要基因型和肝损伤相关性研究[J].国际检验医学杂志，2016， 37（6）：763-764.
[15] 张景皓，王家路，赵 虎.新疆汉族与维吾尔族 HBV 耐药变异类型与基因型研究[J].检验医学，2014，29（10）：1041-1044.
[16] 李步荣，张 彤，李丽华，等.CHB患者HBV基因型及耐药突变基因联合检测临床研究[J].现代检验医学杂志，2015，30（5）：40-43.
[17] 许建平，钟国权.乙型肝炎病毒核苷类药物耐药突变和基因型研究[J].检验医学与临床，2015，12（9）：1240-1242.
[18] 江必武，叶丽华，王平.HBV复制及其基因分型与HBV相关慢性肝病关系的临床研究[J].华中科技大学学报：医学版，2013，42（2）：231-233.
[19] 孙文锦，肖作汉，赵丽芹，等.乙型肝炎病毒基因分型与疾病病情的关系[J].实用肝脏病杂志，2013，16（1）：66-67.
[20] 医学论坛网.标准·方案·指南——2015亚太肝病研究学会/世界卫生组织慢性乙型肝炎防治指南速递[J].中国全科医学，2015，18（21）：2598. |
|
|
|
